Why Abzena?
Trust our focused approach.
Through a comprehensive technology transfer program, we deliver a proven scale-up model to ensure a robust and consistent bioconjugate manufacturing process from clinical to commercial scale.
Abzena provides the specialized analytical method support you need, and the technical rigor necessary, for high-quality therapeutics that meet evolving regulatory expectations. Throughout every phase of development and manufacturing, our analytical methods inform critical decisions that de-risk your program.
We are ready to collaborate with your team to de-risk the pathway to commercialization, ensure manufacturability, and deliver high-quality medicines to patient.
Abzena has a well-established and robust, end-to-end cGMP bioconjugate manufacturing platform in our Bristol, PA facility. Our complex chemistry and bioconjugate manufacturing facility has been meticulously designed to produce high-quality bioconjugates for clinical and commercial use.
Interested in learning more about our fully integrated development and manufacturing capabilities for bioconjugates? Get in touch with our experts today.
Bioconjugate manufacturing involves the production of complex therapeutics that combine biologics with chemical payloads, including antibody-drug conjugates (ADCs), antibody-oligonucleotide conjugates (AOCs), and other targeted therapies. A bioconjugate CDMO provides expertise in process scale-up, analytical development, and GMP bioconjugate manufacturing to ensure consistent product quality from clinical development through commercial production.
Promoting innovation and continuous improvement, we adhere to a framework following ICH guidance and work collaboratively alongside you to support the management of post-approval Chemistry, Manufacturing, and Control (CMC) changes for your product.
We apply a rigorous, science-driven and risk-based methodology to guide your decisions, ensuring all post-approval changes are fully aligned with their intended purpose. Our experienced team develops robust, high-quality data packages designed to streamline and accelerate regulatory review.
Analytical methods are essential to toxicological batch manufacturing, clinical manufacturing, product release, and stability testing. Specialized analytical methods monitor product integrity and stability, providing reliable data that informs early-stage development decisions and mitigates risk prior to clinical trials. Abzena’s GMP manufacturing infrastructure uses validated release and stability methods to support clinical trial material production. Routine testing of critical quality attributes (CQAs) ensures each batch meets stringent regulatory standards throughout clinical development.
Abzena has extensive capabilities in cGMP and non-GMP bioconjugate production. We have expertise in employing single-use technology that allows for rapid turnaround times and cost-effective solutions.
Supporting the robust scaling of your project from clinical through to commercial scale, we are dedicated to manufacturing excellence, delivering small molecule intermediates including bioconjugates and antibody-drug conjugates (ADCs).